TFG-MET fusion has been identified in different tumor types, such as thyroid cancer, glioblastoma, and spindle cell sarcoma.15 Although the therapeutic susceptibility of the TFG-MET fusion has not yet been reported, our study provides clinical evidence for the efficacy of crizotinib in TFG-MET rearranged LUSC. This evidence concerns the gene MET and thyroid cancer.